Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) – January 2019

Stonegate Partners Updated Report – January 2019

Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

BPTH – Certificate of Amendment to Certificate of Incorporation (1-16-19)

BPTH – Certificate of Amendment to Certificate of Incorporation (1-16-19)

Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock (Pricing)